NanoBase™ by Pensive Beauty

Research & Evidence

This page is written for the skeptic. If you formulate for a living or audit supplier claims, you have learned to discount marketing language on sight. Good. NanoBase™ is a real material with a specific design logic, one characterization assay we run on every batch, and a validation roadmap that is honest about what has been measured and what has not. Everything below is stated at the level of confidence the data actually support, and nothing more. Unfamiliar terms are defined in our glossary.

NanoBase™ is a tri-domain nano-colloidal architecture. By design it carries three coexisting colloidal domains, a nanoemulsion domain, a nanoliposomal domain, and a micellar domain, held in a single pourable system that is itself the continuous phase your finished formula is built into. Pensive Beauty manufactures the architecture; brands and contract manufacturers do not make it, they build finished products on top of it. The architecture is an empty chassis, so it is not itself a finished product and cannot be “clinically tested” as sold. What can be evidenced is its design, its characterization, and its adoption, and those are what this page documents.

Published work

Two open-access preprints (Zenodo, CC-BY), self-published and not yet peer-reviewed; they propose a framework and are not evidence of performance. We link them so you can read the primary source, not our summary.

One of these preprints explicitly frames tape-strip sampling, Franz cell diffusion testing, and confocal Raman microscopy as suggested future validation methods rather than results already in hand.

The design thesis, stated honestly

It is worth separating what NanoBase™ updates from what it does not touch. NanoBase™ does not disprove, overturn, or evade any physical law. It operates squarely inside established colloid physics.

Two pieces of well-understood background matter here. Nanoemulsions are kinetically stable rather than thermodynamically stable; they are metastable systems whose longevity is a matter of engineered energy barriers, not of reaching a lowest-energy state, developed in the nanoemulsion work associated with McClements. NanoBase™ lives inside that paradigm. Its electrostatic barrier follows DLVO theory as a design principle by which the system is kept kinetically stable; it is not a claim that the architecture has escaped the thermodynamics that govern every colloid. Separately, the classical packing-parameter picture, associated with Israelachvili, maps a single amphiphile to a single preferred morphology, and the field has long treated the coexistence of multiple morphologies as a loss of control to be engineered out. McClements, Israelachvili, and DLVO theory are cited for the established framework; these authors have not evaluated NanoBase™.

NanoBase™’s contribution is a design contribution, not a physics claim. It treats deliberate, DLS-characterized multi-domain coexistence as something to engineer in on purpose rather than a defect to suppress. In this sense NanoBase™ Logic updates a design convention, the successor logic to Griffin’s 1949 HLB framework, without refuting anything underneath it. We are careful with our verbs. We say the three domains are engineered and DLS-characterized. We do not say we have “proven three coexisting morphologies,” because direct morphological imaging, for example cryo-TEM or SAXS, is a future validation step and not data we currently hold. For the full design argument, see the architecture and NanoBase vs HLB.

How we characterize every batch

Dynamic light scattering (DLS) is the one characterization assay Pensive Beauty runs, and we run it on every batch. DLS reports size, specifically an intensity-weighted hydrodynamic size distribution. It does not image structure or morphology. What we look for is a consistent multimodal size signature that holds batch to batch and is consistent with a multi-domain system rather than a single uniform population. We call that a size signature, not structural proof: confirming morphology directly is a separate step, described below.

Because this page is about honesty, note what we deliberately do not publish. We do not quote a polydispersity index or describe the system as “monodisperse”; a multi-domain architecture is not meant to be monodisperse, and a single tidy number would misrepresent it. We do not publish zeta potential values; the DLVO electrostatic barrier is stated as a design principle, not as a measured figure we are asking you to trust. The multimodal size signature is what we actually measure, so it is what we actually report.

Validation roadmap

Here is the part most suppliers leave out. Because DLS reports size and not structure, the methods that would confirm morphology or test how a finished formula behaves on skin are, for us today, suggested future methods and not data in hand. That set includes direct morphological imaging by cryo-TEM or SAXS, along with tape-strip sampling, Franz cell diffusion studies, and confocal Raman microscopy. Naming them is a commitment, not a result.

The near-term data path runs through the finished formula. NanoBase™ is a chassis; a brand builds its actual product on top of it and then tests that product. Third-party testing of a brand’s finished formula, against that formula’s own claims, is the defensible route to on-skin data, and we will share such results as they become available. We do not put a date on that.

On delivery specifically, we frame the mechanism as deposition, not penetration. Any delivery numbers come from third-party published literature on sub-200nm colloidal carriers, which broadly reports improved deposition and bioavailability relative to coarse emulsions. We offer that only as external, third-party-attributed rationale. It is not NanoBase™’s own measured result, and it is not a head-to-head comparison against an HLB-built system.

An independent adoption signal

Included in the Medical Aesthetics Certificate Program curriculum at Eastern Virginia Career College, effective 2027; the educator endorsement is offered in a personal capacity, not on behalf of the college or any board. That adoption is, to our knowledge, the first tri-domain nano-delivery architecture formally incorporated into an accredited medical-aesthetics certificate program (effective 2027). We state it as an adoption fact, never as a scientific-priority claim.

Speaking in that personal capacity, the educator characterized the tri-domain architecture as a material advancement over legacy emulsion systems, and spoke to its scientific merit, technical depth, and educational value. We present that as informed professional opinion, not as clinical or performance data.

What we claim, and what we do not

What we claim:

  • NanoBase™ is a tri-domain nano-colloidal architecture whose three coexisting domains are engineered by design and characterized by DLS.
  • We run DLS on every batch and look for a consistent multimodal size signature.
  • The system is kept kinetically stable within established colloid physics, using a DLVO-informed electrostatic barrier as its design principle.
  • Our design logic is documented in two open-access Zenodo preprints, and NanoBase™ has been incorporated into an accredited medical-aesthetics certificate program, effective 2027.

What we do not claim:

  • We do not claim skin penetration or transdermal delivery; our framing is deposition, and on-skin performance is tested at the finished-formula level by the brand, not by us.
  • We do not claim the chassis is “clinically tested,” publish a polydispersity index or a “monodisperse” descriptor, or publish zeta potential values.
  • We do not claim to have imaged the three morphologies; DLS reports size, not structure, and cryo-TEM, SAXS, tape-strip, Franz cell, and confocal Raman are suggested future validation, not current data.
  • We do not present the preprints as evidence of performance; they propose a framework, and performance questions are answered by third-party testing of a brand’s finished formula, not by us.

Request the documentation

Verified brands, formulators, and buyers can request our full technical documentation package, including representative DLS characterization, or a sample of the architecture to evaluate directly. Our capacity is a boutique nanoscience lab and a 10,000 sq ft production facility, enough to support serious evaluation and scale-up conversations.